On September 2, 2021 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following investor conferences in September (Press release, MacroGenics, SEP 2, 2021, View Source [SID1234587172]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a panel discussion, Novel Antibodies and Protein Therapies in Oncology, on Thursday, September 9, 2021, at 1:25 pm ET. Management will also participate in one-on-one meetings.
H.C. Wainwright 23rd Annual Global Investment Conference. MacroGenics management is scheduled to participate in a fireside chat, which will be available for on-demand viewing from September 13-15, 2021. In addition, management will participate in one-on-one meetings.
2021 Cantor Virtual Global Healthcare Conference. MacroGenics management is scheduled to participate in a fireside chat on Thursday, September 30, 2021, at 12:40 pm ET, and will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.